FDAnews Device Daily Bulletin
Medical Devices / Submissions and Approvals

SOPHiA GENETICS Hematological Disease Detection Test Achieves CE-IVD Marking

Feb. 9, 2018

Switzerland-based molecular diagnostic company SOPHiA GENETICS received CE-IVD Mark for its Myeloid Solution to aid in the diagnoses of hematological diseases, such as leukemia.

The molecular diagnostic testing solution “comprehensively covers genes associated with hematological disorders and provides clinicians with a complete solution which rapidly and precisely analyzes their patients’ DNA,” the company said.

It uses patients’ individual molecular footprint to provide personalized treatment options.

View today's stories